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Abstract
MicroRNAs are single-stranded non-coding RNAs that simultaneously down-modulate the expression of multiple genes
post-transcriptionally by binding to the 39UTRs of target mRNAs. Here we used computational methods to predict
microRNAs relevant in breast cancer progression. Specifically, we applied different microRNA target prediction algorithms to
various groups of differentially expressed protein-coding genes obtained from four breast cancer datasets. Six potential
candidates were identified, among them miR-223, previously described to be highly expressed in the tumor
microenvironment and known to be actively transferred into breast cancer cells. To investigate the function of miR-223
in tumorigenesis and to define its molecular mechanism, we overexpressed miR-223 in breast cancer cells in a transient or
stable manner. Alternatively we overexpressed miR-223 in mouse embryonic fibroblasts or HEK293 cells and used their
conditioned medium to treat tumor cells. With both approaches, we obtained elevated levels of miR-223 in tumor cells and
observed decreased migration, increased cell death in anoikis conditions and augmented sensitivity to chemotherapy but
no effect on adhesion and proliferation. The analysis of miR-223 predicted targets revealed enrichment in cell death and
survival-related genes and in pathways frequently altered in breast cancer. Among these genes, we showed that protein
levels for STAT5A, ITGA3 and NRAS were modulated by miR-223. In addition, we proved that STAT5A is a direct miR-223
target and highlighted a possible correlation between miR-223 and STAT5A in migration and chemotherapy response. Our
investigation revealed that a computational analysis of cancer gene expression datasets can be a relevant tool to identify
microRNAs involved in cancer progression and that miR-223 has a prominent role in breast malignancy that could
potentially be exploited therapeutically.
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Introduction
Breast cancer is the tumor with the highest incidence in women
[1]. However, recently, life expectancy improved enormously,
thanks to early detection, better characterization of tumor
molecular parameters and more accurate therapy [2]. Breast
cancer is a heterogeneous group of neoplasms derived from the
epithelium surrounding the milk ducts [3]. This heterogeneity led
to pathology-driven classifications, recently complemented by
molecular characterizations. In fact, based on protein-coding gene
expression profiling, breast tumors can be classified at least in
three major subtypes: luminal or estrogen receptor positive (ER+),
basal or triple negative and human epidermal growth factor
receptor 2 positive (HER2+) breast tumors [4,5,6,7], which are
associated with different clinical outcome. This classification helps
in addressing clinical treatment, but the identification of patients
that are prone to recur or to develop therapy resistance is far from
being achieved. Recently, new tumor features such as tumor-
stroma composition [8,9,10,11,12] and microRNA expression in
tumors or stroma cells were shown to be relevant for breast cancer
progression and they deserve deep investigation [13,14,15,16,17].
Stroma composition and tumor-stroma interaction and co-
evolution have been found to mediate cancer progression based on
chemokine and hormone secretion [18], as well as on exosome or
microvesicle production [19,20].
MicroRNAs are small endogenous non-coding RNAs able to
post-transcriptionally downregulate expression of multiple specific
target genes by binding to the 39 UTRs of their mRNAs causing
destabilization, degradation or translation inhibition [21]. Several
microRNAs, were found to control breast cancer tumor formation
and progression, functioning as oncomiRs or tumor suppressor
miRs or metastamiRs. Examples are miR-21, miR-155, miR-10b,
miR-373, miR-206, miR-17-5p, miR-200 family, let7, miR-34 and
miR-31 [22,23,24,25,26,27,28,29,30,31]. MicroRNA expression
profiling is of great help for tumor classification since they seem to
classify tumors more precisely than protein-coding genes, accord-
ing to lineage and differentiation status [32,33]. MicroRNAs can
also represent a relevant link between tumor and stroma cells. In
fact, microRNAs are often present in exosomes or microvesicles
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e84859
[34,35] produced by stroma cells and transferred into tumor cells,
affecting malignancy. As a consequence, it is particularly
important to identify microRNAs involved in tumor-stroma co-
evolution.
The focus of our work was the identification of microRNAs,
produced by tumor or stroma cells, involved in breast cancer
malignancy using a target reverse gene expression approach starting from
breast cancer gene expression datasets. This approach unravelled
a group of six microRNAs, miR-19ab, miR-200bc, miR-203,
miR-21, miR-223 and miR-340, predicted to be deregulated
during breast cancer progression. Among them, we studied the
function and the molecular mechanism of miR-223 in breast
cancer malignancy.
Materials and Methods
Human Breast Cancer Datasets
Four datasets were used for differential protein-coding gene
expression analysis and microRNA prediction: van de Vijver-NKI
(http://bioinformatics.nki.nl/data.php) containing expression of
295 consecutive breast tumors, not treated with adjuvant therapy
[36]; Pawitan-Gene Expression Omnibus (GEO) series GSE1456
(http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc =GSE1456), 159 patients [37] and Miller datasets, GEO
series GSE3494 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc =GSE3494), 251 patients [38]: in these two cases tumor
selection was done on consecutive samples based on RNA quality
and tumor tissue quantity; Desmedt, GEO series GSE7390
(http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc =GSE7390), 198 samples of lymph-node negative patients
[39].
Differential Expression Analysis
The gene expression datasets listed above were normalized
using RMA as implemented in the affy package [40] of
Bioconductor [41]. Only probes unambiguously linked to unique
gene IDs were evaluated. When multiple probes annotated to the
same gene were present only the probe having the highest median
expression value was considered. For Affymetrix platforms we used
manufacturer-provided annotation, version 30, while for NKI
dataset we considered the annotation file present on the website.
The correspondence to Entrez and Ensemble gene IDs was
obtained from BioMart or Entrez gene ftp site. Genes having a p-
value lower than 0.05 after Wilcoxon rank-sum and Benjamini-
Hochberg correction for multiple testing were used to obtain
separate lists of up-regulated and down-modulated genes accord-
ing to 5 years disease free survival (DFS) status for each dataset.
The analysis was performed independently for Entrez and
Ensembl gene ID annotated probes to avoid a bias in the next
steps, since the results of each prediction algorithms were given in
terms of one of these two gene annotation systems.
microRNA Prediction Analysis
TargetScan, release 5.0, Miranda, release September 2008,
MicroCosm (miRBase) Targets v5 and DIANA-microT v3.0
prediction algorithms were used to identify predicted microRNA
targets [42,43,44,45]; for all predictions and microRNA nomen-
clature we referred to miRBase v13. To evaluate enrichments in
microRNA seeds, among the differentially expressed gene lists, we
used an exact Fisher test. We adjusted the p-values for multiple
testing with the Benjamini-Hochberg correction and filtered out
the results having a corrected p-value lower than the one
corresponding to the 0.99 percentile of the p-value distribution,
obtained by randomizing the association between microRNAs and
target genes. The highest nominal p-value considered after
randomization was between 0.0054 and 0.0078 depending on
the prediction algorithm used. Only microRNAs predicted and
effectively expressed in breast cancer samples according to Cimino
et al. [46] dataset were considered for enrichment analysis.
When we compared our results with what obtained using the
method published in [47], t-value was calculated for all the genes
present in at least 60% of the samples, according to presence or
absence, as evaluated in the PanP Package (http://www.
bioconductor.org/packages/2.12/bioc/html/panp.html). Then, a
Kolmogorov–Smirnov test was performed and p-values lower then
0.05 (after the Benjamini-Hochberg correction) were considered
significant to identify relevant predictions for the previously
identified microRNAs (six). All the analyses were performed using
R language [48].
Cell Culture
HEK293, MDAMB231, MCF7 and HeLa cells were obtained
from American Type Culture Collection (ATCC); Mouse Embryo
Fibroblasts (MEFs) were derived from C57/B6 E13.5 mouse
embryos; all maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM) containing 10 mM Glutamax and 4.5 g/L glucose
(DMEM GlutamaxTM, GIBCO Invitrogen Life Technologies,
Carlsbad, CA), supplemented with 10% heat-inactivated FCS
(Biochrom AG, Berlin, DE), 1 mM sodium pyruvate, 25 mM
HEPES pH 7.4 and 100 mg/mL gentamycin (all from GIBCO
Invitrogen Life Technologies, Carlsbad, CA). T47D were obtained
from ATCC and maintained in Roswell Park Memorial Institute
(RPMI) medium enriched as described above for DMEM medium
plus 5 mg/mL insulin. SUM149PT cells were a gift of Prof. SP
Ethier and were cultured as described in [49]. In experiments in
which Conditioned Medium (CM) was used, MDAMB231 cells
were grown, at different time points, in CM collected from MEFs
(P3) or HEK293 cells stably transduced (or not) with pLemiR-
empty (empty) or pLemiR-miR-223 (miR-223) expressing lentivi-
ral vectors. For all biological assays in which we used HEK293
cells CM medium on MDAMB231 cells, starvation for 3 days was
performed in HEK293 cell cultures.
Human Breast Tumor Samples
Paraffin embedded tumor specimens were selected from the
Tumor Bank of the Department of Obstetrics and Gynecology,
University of Turin, obtained from patients who underwent
primary surgical treatment. Appropriate ethical approval was
obtained for this study [46]. These samples were used to extract
RNA via punches as indicated below.
Reagents, Antibodies and Primers
RNAi: si-STAT5A (Hs_STAT5A_5) and si-control (AllStars
Negative Controls) (from QIAGEN Stanford, CA). microRNA
precursors: Pre-miRTM microRNA Precursor Molecules for
Negative Control#1, Hsa-miR-223 (PM12301) or Hsa-miR-203
(PM10152) and Hsa-miR-196 (PM10068) used as unrelated
microRNAs (controls for some experiments). microRNA detec-
tion: TaqManHMicroRNA Assays for Hsa-miR-19a (ID 000395),
Hsa-miR-200b (ID 002251), Hsa-miR-203 (ID 000507), Hsa-miR-
21 (ID 000524), Hsa-miR-223 (ID 002295), Hsa-miR-340 (ID
000550), U6 snRNA (ID 001973) (all from Applied Biosystems,
Foster City, CA). Primary antibodies: anti-STAT5A L-20,
anti-N-RAS mAb F155, anti-GAPDH Ab V-18 (from Santa Cruz
Biotechnology, Santa Cruz, CA), and anti-a-TUBULIN mAb B5-
1-2 (from Sigma, St Louis, MO), anti-VINCULIN kindly provided
by G. Tarone (Molecular Biotechnology Center, University of
Torino, Italy), anti-ITGA3 pAb 8-4 B7 gently provided by Mike
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DiPersio [50]. Secondary antibodies: goat anti-mouse IgG
HRP-conjugated, goat anti-rabbit IgG HRP-conjugated, donkey
anti-goat IgG HRP-conjugated (all from Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). All antibodies were used at the producer’s
suggested concentrations. Adhesion: Collagen IV, Fibronectin,
Laminin from Sigma Aldrich, St Louis, MO. Cell death
reagents: FITC-conjugated Annexin V and PI were from
Bender MedSystems (Vienna, Austria). APC-conjugated Annexin
V was from BD Biosciences (Bedford, MA). Tetramethylrhoda-
mine methyl ester (TMRM) was from Molecular Probes (Invitro-
gen, Carlsbad, CA). Paclitaxel (PTX) was an ONCOTAIN
trademark (MaynePharma, AU) and Doxorubicin was from Sigma
Chemical Co. (St Louis, MO). Z-VAD-FMK was from Promega
(Madison, WI). Primers: miR-223 fw: ccgctcgagGAGCTTC-
CAGCTGAGCACTGGG; miR-223 rev: cgacgcgt-
TATTGCGCCCCCATCAGCACT; Stat5a fw: aaactagtTT-
GACTCCCGCCTCTCGCCC; Stat5a rev:
ttacgcgtCCTCTTCTCATCCCCACCTCCCT; Stat5a mut
sense: tttagtaaggctgtgtacacgggcccctttgcaggcatgcatgtg; Stat5a mut
antisense: cacatgcatgcctgcaaaggggcccgtgtacacagccttcataaa.
Vector Construction and Lentiviral Infections
The 39UTR of STAT5A, previously generated by PCR
amplification of the full length 39UTR from human cDNA of
MDAMB231 cells was inserted in the pMIR REPORTTM
luciferase vector (Ambion, Austin, TX) generating the STAT5A
vector. miR-223 binding site in the 39UTR was mutagenized
(STAT5AMUT) using the QuickChange Site-Directed Mutagen-
esis kit (Stratagene, Cedar Creek, TX) according to the
manufacturer’s instructions.
The human STAT5A cDNA, containing the full length 39
UTR, was kindly obtained from Prof. B. Groner (Goethe
University of Frankfurt am Main, Germany) and cloned into the
pCMV-EGFP vector after GFP removal. miR-223 binding site on
STAT5A 39UTR was then mutagenized as described for pMIR
REPORT-luciferase-STAT5A.
The human pre-miR-223sequence (a 559 bp fragment contain-
ing the premiR sequence) was amplified from genomic DNA
(MDAMB231) and cloned into pLemiR-tRFP (Open Biosystems,
Huntsville, AL) vector to obtain pLemiR-223 (still containing
tRFP) vector. Lentiviruses were produced by calcium phosphate
transfection of 293 T cells with 20 mg of specific vector together
with 15 mg packaging (pCMVdR8.74) and 6 mg envelope
(pMD2.G-VSVG) plasmids according to Trono’s lab protocol
(http://tronolab.epfl.ch). Supernatant was harvested 48 h post-
transfection, filtered with 0.45 mm filters and used to infect
3.56105 cells in 6-well plates, in presence of 8 mg/mL Polybrene
(Sigma-Aldrich, StLouis, MO).
Transient Transfections of Pre-microRNAs and siRNAs
To obtain transient pre-miR, or siRNA expression, cells were
plated in 6 or 12 well plates at 50–70% confluency and transfected
using HiPerFect Transfection Reagent (QIAGEN, Stanford, CA)
reagent, according to manufacturer’s instructions, with 75 nM of
pre-miR or 100 nM siRNA. Cells were tested for microRNA or
protein-coding gene overexpression/knockdown 48 h later. For
transient cDNA overexpression, cells were plated at 90%
confluency and transfected 24 h later using Lipofectamine
2000TM reagent (Invitrogen Life Technologies, Carlsbad, CA).
RNA Isolation and qRT-PCR for microRNA or mRNA
Detection
Total RNA was isolated from cells using TRIzolH Reagent
(Invitrogen Life Technologies, Carlsbad, CA) according to
manufacturer’s protocol. Instead, RNA from formalin-fixed
paraffin embedded breast tumor specimen punches was obtained
as follows. Microscopical slides of paraffin inclusions were scanned
with Panoramic Desk (3DHistech, Euroclone, Pero, MI, Italy) and
corresponding virtual slides were evaluated with the Panoramic
View program (3DHistech). From each tumor 2 areas of sampling
(1 mm in diameter) were marked on the virtual slides. Virtual
slides with sampling markers were transferred to the TMA
instrumentation (Panoramic Desk, 3DHistech). Low magnification
images of the slides were matched with the corresponding
histological block inclusions and the selected areas were punched
out with a 1 mm punching needle. From each block 1 mm cores
were collected in custom vials, inserted in the waste bin receptacle,
properly labeled and RNA isolated using acid guanidinium
thiocyanate-phenol-chloroform extraction method. All RNA
quantitations were performed using the NanoDrop-1000 spectro-
photometer (Nanodrop, Wilmington, DE). qRT-PCRs for detec-
tion were performed with the indicated TaqManH MicroRNA
Assays (Applied Biosystems, Foster City, CA) on 10 ng total RNA
according to the manufacturer’s instructions. Quantitative nor-
malization was performed on the expression of the U6snoRNA.
The relative expression levels between samples were calculated
using the comparative delta CT (threshold cycle number) method
(22DDCT) with a control sample as reference point [51]. RNA
samples from monocytes (CD14), dendritic cells (DC, TNFa-
activated DC), activated T-cells (anti-CD3/CD28), purified T-cells
(CD8), hematopoietic stem cells (CD34) and mesenchymal cells
(MSC) were kindly provided by A. Cignetti (MBC, Torino, Italy).
Migration and Invasion Transwell Assays
To measure migration 86104 MDAMB231 were seeded in
serum-free media in the upper chambers of cell culture inserts
(transwells) with 8.0 mm pore size membrane (24-well format,
Becton Dickinson, NJ). Invasion assays were performed using
BioCoatTMMatrigel Invasion Chambers with 8.0 mm pore size
membrane (Becton Dickinson, NJ). For migration and invasion the
lower chambers were filled with complete growth media. After 20–
24 h, the migrated cells present on the lower side of the membrane
were fixed in 2.5% glutaraldehyde, stained with 0.1% crystal violet
and photographed using an Olympus IX70 microscope. Migration
and invasion were evaluated by measuring the area occupied by
migrated cells using the ImageJ software (http://rsbweb.nih.gov/
ij/) [52].
Adhesion Assays
To test adhesion, 56104 cells/well were seeded directly on
5 mg/mL collagen IV or 10 mg/mL fibronectin or 5 mg/mL
laminin (all from Sigma-Aldrich, St Louis, MO) precoated 96-well
plates, for 1 h at 37uC. Cells were then washed thoroughly to
remove non adherent cells, fixed with methanol and stained with
haematoxylin and eosin (Diff-Quik, Medion Diagnostics, Dudin-
gen, CH). Wells were photographed using Olympus IX70
microscope and the area occupied by the adherent cell was
measured by using the ImageJ software (http://rsbweb.nih.gov/ij/
) [53].
Proliferation Assays
56103 cells/well were plated in 96-well plates in complete
medium and starved for 12–24 h. Complete medium was then
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added and cells were allowed to grow for 24, 48, 72, 96 hours,
fixed with 2.5% glutaraldehyde and stained with 0.1% crystal
violet. The dye was solubilised using 10% acetic acid and optical
density measured directly in plates using GloMax Luminometer
(Promega, Madison, WI) at 570 nm wavelength [54].
Anoikis Assay
Cells were plated on a 2% agarose pad in serum-free medium
for 48 h, collected, washed in PBS buffer, resuspended in 10 mM
Hepes, 150 mM NaCl, 5 mM CaCl2 buffer containing FITC-
conjugated Annexin-V (Bender MedSystems, GmbH) and
200 nM tetramethyl-rhodamine-methyl-ester (TMRM, Molecular
Probes, Invitrogen, CA) and incubated at 37uC for 20 minutes.
Flow cytometry analysis of anoikis was carried out using a
FACSCalibur flow cytometer (Becton Dickinson, NJ). Data
acquisition was performed using CellQuest software (Becton
Dickinson, NJ) and data analysis with WinMDI software (version
2.8, Scripps Institute, CA). Results were displayed in bidimen-
sional plots, with gates indicating the percentages of healthy and
dead cell populations [55].
Cell Death Assays
1–1.56105 MDAMB231 were plated in 12 well plates and
transfected as already described, 24 h after cells were washed and
grown in complete medium with or without 1 mM Paclitaxel
(PTX) or 1 mM Doxorubicin (DOXO) for 48 h. When present, Z-
VAD-FMK inhibitor was used at 20 mM final concentration in the
presence of 1 mM PTX. The supernatant was collected and cells
were washed once in phosphate-buffered saline (PBS) detached by
trypsinization and added to the supernatant suspension. Labeling
and analysis was performed as in anoikis analysis.
Luciferase Assays
6.56104 cells were cotransfected with 50 ng of the pMIR
REPORTTM (Ambion, Austin, TX) Firefly Luciferase constructs
containing the 39UTRs of the indicated miR-223 potential target,
20 ng of pRL-TK Renilla Luciferase normalization control
(Promega, Madison, WI) and 75 nM of the indicated pre-miR
using LipofectamineTM2000 (Invitrogen Life Technologies, Carls-
bad CA). Lysates were collected 48 h after transfection and Firefly
and Renilla Luciferase activities were measured with a Dual-
Luciferase Reporter System (Promega, Madison, WI).
Protein Preparation and Immunoblotting
Total protein extracts were obtained using a boiling buffer
containing 0.125 M Tris/HCl, pH 6.8 and 2.5% sodium dodecyl
sulphate (SDS). 25 or 50 mg proteins were separated by SDS
polyacrylamide gel electrophoresis (PAGE) and electroblotted on
to polyvinylidene fluoride (PVDF) membrane Immobilon-P
(Millipore, Billerca MA). Membranes were blocked in 5% non-
fat milk Phosphate buffered saline PBS-Tween buffer (137 mM
NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.46 mM KH2PO4, 0.1%
Tween-20) for 1 h at 37uC, then incubated with appropriate
primary and secondary antibodies in 1% milk or BSA (Sigma)
PBS-Tween buffer, respectively overnight at 4uC and for 1 h at
room temperature and visualized by enhanced chemiluminescence
(ECLH, GE Healthcare Life Sciences, GmbH).
Statistical Analyses of Biological Samples
Unless otherwise noted, data are presented as mean6 Standard
Error of the Mean (SEM) and two tailed Student’s t test was used
for comparison, with * = p,0.05; ** = p,0.01; *** = p,0.001
considered to be statistically significant. n.s. indicates a not
statistically significant p-value.
Ingenuity Pathway Analysis
Only miR-223 targets predicted by at least two out of 4
prediction algorithms (TargetScan, release 5.2, Miranda, release
August 2010, MicroCosm (miRBase) Targets v5 and DIANA-
microT v3.0) were considered for Ingenuity Pathway Analysis
(IPA) [42,43,44,45]. The Ingenuity Pathways Knowledge Base
(http://www.ingenuity.com/) is currently the world’s largest
database of knowledge on biological networks, with annotations
curated by experts. We exploited this database to look for
enrichments in cellular functions, pathways or disease related
genes among miR-223 putative targets. Enrichment significance in
Signaling pathways analysis is shown as the negative Log10 of the
p-value. The p-value is calculated with the right-tailed Fisher’s
Exact Test. Ratio is calculated as the number of predicted targets
over the total gene number of each pathway.
Results
6 microRNAs are Predicted to be Involved in Breast
Cancer Progression
To infer a potential correlation between deregulation of
microRNAs and breast cancer progression through the analysis
of gene expression data, we set up the pipeline shown in Figure 1A.
First, we computed the lists of up and down-modulated genes (kept
separated) from four breast cancer public available datasets,
comparing patients with (R+) or without (R-) disease relapse within
five years from surgery. Second, we used the lists of up or down
regulated genes, each one including at least 30 differentially
expressed genes (only two datasets led to this requirement,
Figure 1A), to predict enrichments in microRNA seeds in mRNA
39UTRs using four prediction algorithms (TargetScan v 5.0,
Miranda September 2008, MicroCosm (miRBase) Targets v5 and
DIANA-microT v3.0). Third, we prioritized the predicted
microRNAs effectively expressed in breast cancer samples as in
[46], obtained from two datasets [36,37] and by at least two
different algorithms. In this way, a group of six microRNAs, miR-
19ab, miR-200bc, miR-203, miR-223, miR-21 and miR-340 (as
from miRBase v13) or miR-19ab-3p, miR-200bc-3p, miR-203a,
miR-223-3p, miR-21-5p and miR-340-5p (as from miRBase v20)
was revealed. In parallel, we used the target reverse gene expression
approach proposed in [47] to verify our microRNA predictions. In
this way, we used three datasets [37,38,39] for microRNA
predictions and, once more, miR-19ab, miR-200bc, miR-203,
miR-223, miR-21and miR-340 were predicted (Table 1).
Expression of these small RNAs was evaluated by qRT-PCR in
a panel of human breast cancer cells in culture, including ER2/
highly aggressive MDAMB231 and SUM149PT or ER+/poorly
aggressive MCF7 and T47D cell lines (Figure 1B, log2 scale). No
major differences were evidenced considering malignancy or ER
expression. All tumor cells resulted almost empty for miR-223 and
miR-340, while showed variable levels for miR-200b and miR-203
and higher levels of miR-19 and miR-21. Considering that tumor-
associated stroma cells produce microRNAs that can be
transferred into tumor cells through microvesicles and cell-cell
junctions, we evaluated the expression of the same microRNAs by
qRT-PCR in stroma cells such as monocytes (CD14), dendritic
cells treated or not with Tumor Necrosis Factor alpha (DC, TNFa
activated DC), activated T-cells (CD3/CD28), purified T-cells
(CD8), hematopoietic stem cells (CD34) and mesenchymal stem
cells (MSC). While for miR-200b, miR-203 and miR-340
expression was low also in microenvironmental cells, for miR-
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223 a high expression (10 to 5000 fold increase) was observed in
stroma cells compared to breast tumor cells. miR-19a and miR-21
were highly expressed also in some stroma cells, in particular in
activated dendritic cells (Figure 1C, log2 scale). Since miR-223 was
the only putative small RNA to be expressed uniquely in stroma
but not in tumor cells in culture, we hypothesized a possible
transfer of miR-223 from stroma to tumor cells within the human
tumor mass. To verify our hypothesis, we first evaluated miR-223
expression in pools of RNA derived from tumor or stroma
components of human breast tumor samples following dissections
(punches) performed in paraffin embedded tumors or stroma as
shown in Figure S1A. As shown in Figure S1B, good expression of
miR-223 is visible in tumor or stroma components of breast cancer
samples as well as in lymph nodes, while MDAMB231 cells are
empty. High levels of miR-21, used as a control, were found in all
samples and in MDAMB231 cells. In a second approach, we
evaluated miR-223 expression in MDAMB231 cells grown for 48
hours in presence of a conditioned medium (CM) derived from
mouse embryonic fibroblasts (MEFs) or HEK293 cells or from the
same cells previously transduced with miR-223 lentivirus vectors
(expression levels in Figure S2A–B). Good/high levels of miR-223
expression were found in MDAMB231 cells when CM from miR-
223-overexpressing or control MEFs or HEK293 cells was used,
compared to normal growth medium (Figures 2A, B and S2)
suggesting a transfer of miR-223 from MEFs or HEK293 cells to
MDAMB231 cells. To note that miR-223 was not endogenously
expressed by HEK293 cells, while expression was found in MEFs.
miR-223 Impairs Tumor Cell Migration and Invasion
Given that miR-223 is expressed in stroma cells, that it is
expressed in tumor samples and that it could be transferred to
breast cancer cells from surrounding cells, we evaluated miR-223
biological functions or target gene expression in MDAMB231 or
SUM149PT cells. This was done by overexpressing miR-223 in
tumor cells or by growing them in presence of conditioned
medium (CM) derived from cells overexpressing miR-223 (see
above). When MDAMB231 or SUM149PT cells were stably
transduced with miR-223 overexpressing (miR-223) or empty
(empty) lentiviral vectors, or transiently transfected with miR-223
precursors or controls (pre-miR-223, pre-control), or grown in
miR-223 overexpressing or control HEK293 CM, increased (200
to 10,000 folds) levels of miR-223 were obtained (Figure S2C–F).
When MDAMB231 cell proliferation or adhesion on Collagen
IV, Fibronectin, Laminin or Plastic was analyzed no differences
were observed between overexpressing and control cells (data not
shown). Instead a 10% to 40% decrease in cell migration and
invasion was found in transwell assays with or without matrigel
(Figure 3A–F and S3) in presence of miR-223 overexpression or
CM. These findings suggest an anti-invasive function of miR-223
expressed in tumor cells or transferred from surrounding cells.
miR-223 Expression Enhances Cell Death in Anoikis
Conditions or in Presence of Chemotherapeutic Drugs
To evaluate the effects of miR-223 up-regulation on
MDAMB231 metastatic cell survival in the blood flow, we
measured cell viability in absence of anchorage (anoikis) and
serum for 48 hours by Annexin V-FITC and TMRM staining in
FACS analysis and observed a 10–15% increase of cell death
(Figure 4A and S4A). Considering that chemotherapy is the main
therapeutic strategy against tumor cells, we investigated the effects
of miR-223 overexpression on cell death induced by doxorubicin
(DOXO) or paclitaxel (PTX) for 48 hours. Increased cell death
was observed in MDAMB231 cells transiently transfected with
miR-223 precursors or controls (pre-miR-223, pre-control and
unrelated-pre-miR) (Figure 4B, C and S4B, C). Similar results
were obtained when MDAMB231 cells were grown for 48 hours in
the presence of CM derived from miR-223 overexpressing
HEK293 (HEK) cells (Figure 4D and S4D). As a control of cell
death, we performed an experiment with MDAMB231 cells
transiently transfected with miR-223 precursors or controls (pre-
miR-223, pre-control) in which cells were kept or not in presence
of PTX and ZVAD, a caspase inhibitor. While no effect on cell
death was observed for ZVAD in absence (Basal+ZVAD) of PTX,
a cell death inhibitory effect was observed in presence of PTX
(PTX+ZVAD), for miR-223 overexpressing cells compared to
controls (Figure 4E and S4E, F).
Figure 1. Prediction of miRs involved in breast cancer progression and their expression in cells. (A) Four public datasets of primary
breast cancers were used to identify differentially expressed genes comparing patients with or without disease relapse, five years post-surgery
(DFS =disease free survival). An hypergeometric test was applied to reveal microRNA seed enrichments, according to the predictions provided by at
least two algorithms among TargetScan, Miranda, miRBase (MicroCosm Targets) and DIANA-microT and six miRs were identified. (B–C) Expression of
the six predicted microRNAs in breast cancer cell lines (B), such as ER- highly aggressive, MDAMB231 and SUM149PT; ER+ non invasive, MCF7 and
T47D, and stroma cells (C), such as monocytes (CD14), dendritic cells (DC, TNFa activated DC), activated T-cells (CD3/CD28), purified T-cells (CD8),
hematopoietic stem cells (CD34) and mesenchymal cells (MSC). Results are presented in a log2 scale, as fold changes (mean6SD) relative to the delta
CT mean of triplicates for each biological sample. Delta CTs were obtained after normalization on U6sno RNA level. SD= standard deviation;
CT = threshold cycle number. TNFa=Tumor necrosis factor alpha.
doi:10.1371/journal.pone.0084859.g001
Table 1. Six microRNA prediction occurrence in datasets according to [47].
Datasets
hsa-miR-
19ab-3p
hsa-miR-
200bc-3p
hsa-miR-
203a
hsa-miR-
21-5p
hsa-miR-
223-3p
hsa-miR-
340-5p
Desmedt C et al. Clin Cancer Res
2007 GSE 7390
– – – x(2) x(1) x(2)
Miller LD et al. Proc Natl Acad USA
2005 GSE 3494
x(3) x(3) x(3) x(3) x(3) x(3)
Pawitan Y et al.Breast Cancer Res
2005 GSE 1456
x(3) x(3) x(3) x(3) x(3) x(3)
Significant enrichments of our six microRNAs among genes expressed in Recurrent (+) versus Non-Recurrent (2) samples, in the indicated breast cancer datasets, as
evaluated by [47]. X = predicted. 2=non-predicted. In parenthesis we indicate the number of algorithms able to predict the occurrence.
doi:10.1371/journal.pone.0084859.t001
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Figure 2. miR-223 expression in MDAMB231 cells grown in Conditioned Medium from miR-223 overexpressing cells. miR-223 levels
were measured in MDAMB231 cells grown in normal culture conditions (Growth medium) or in Conditioned Medium (CM) derived from Mouse
Embryonic Fibroblasts (MEF) or Human Embryonic Kidney cells (HEK293-HEK) for 48 hours (A). Alternatively, CM was derived from the cells in (A)
stably transduced with miR-223 overexpression (miR-223) lentiviral vectors (B). Results are presented as fold changes (mean6SD) relative to nomal
growth conditions. Delta CTs were obtained after normalization on U6sno RNA level. SD = standard deviation; CT = threshold cycle number. Three
biological experiments were performed, each with three technical triplicates. Statistics was performed on technical triplicates of one representative
biological experiment.*P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0084859.g002
Figure 3. miR-223 reduces cell migration and invasion. Transwell migration (A–B–C) or matrigel invasion (D–E–F) assays. MDAMB231 cells
were transfected with miR-223 or their negative controls (pre-miR-223 or pre-control) or stably transduced with pLemiR empty (empty) or miR-223
overexpression (miR-223) vectors or pre-treated for 48 h with conditioned medium (CM) collected from stably transduced HEK293 (HEK) cells with the
above mentioned vectors (CM HEK empty or CM HEK miR-223). Results are shown as mean6SEM (standard error mean) of the area covered by
migrated cells (A–F). Three independent biological experiments were performed in triplicate (A–F). Triplicate means, normalized on controls, in pools
of 3 (A–B–C–D) or 2 (F–G) comparable biological experiments are shown and used for statistics. *P,0.05; **P,0.01; ***P,0.001; ns = not significant.
doi:10.1371/journal.pone.0084859.g003
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miR-223 Affects Signal Transduction Pathways Involved
in Cell Death and Directly Targets STAT5A
To identify diseases, functions and pathways controlled by miR-
223, we used the pool of 1995 miR-223 predicted targets
(predictions by two out of the following four algorithms,
TargetScan v5.2, Miranda, August 2010, MicroCosm (miRBase)
Targets v5 and DIANA-microT v3) to run an Ingenuity Pathway
Analysis (IPA). Cancer (582 genes) resulted the top enriched disease
while Cell Death and Survival (497 genes) was the most enriched
cellular function as shown in Table 2. Moreover, an analysis on
Figure 4. miR-223 enhances anoikis and chemotherapy induced cell death. MDAMB231 cells were grown for 48 h on an agar pad (A) or in
complete medium with Doxorubicin (DOXO) (B) or Paclitaxel (PTX) (C) after transient transfection with miR-223 or with unrelated miR precursors or
their negative controls (pre-miR-223 or unrelated pre-miR or pre-control). Alternatively MDAMB231 were grown for 48 h in conditioned medium (CM)
collected from HEK293 (HEK) cells stably transduced with pLemiR empty (empty) or miR-223 overexpression (miR-223) vectors. MDAMB231 cells were
further transferred to regular medium without (Basal) or with PTX for 48 h and cell death was analyzed (D). To control chemotherapy-induced cell
death, MDAMB231 cells were treated as in (C) in presence or absence of ZVAD, a caspase inhibitor (E). The percentage (%) dead cells displayed in
histograms as mean6SEM (standard error mean) was evaluated by TMRM and AnnexinV-FITC or -APC stainings in a FACS analysis. At least three
independent biological experiments were performed in duplicate. Duplicate means relative to three or more pooled biological experiments are
shown and used for statistics. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0084859.g004
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signaling pathways revealed an enrichment for many pathways
including STAT and RAS family members as well as phosphatases
and kinases (i.e. PIK3C2A, PIK3R1-3, PTPN11) in the top 10
pathways (Figure 5A). ITGA3, NRAS, STAT5A (all miR-223
predicted targets) protein expression was evaluated in stably or
transiently miR-223 overexpressing (miR-223 or pre-miR-223) or
control (empty or pre-control) MDAMB231 or SUM149PT cells
(Figure 5B). A down-modulation of 60–80%, 28–50% and 28–
40% was observed respectively for ITGA3, NRAS and STAT5A
in miR-223 overexpressing cells. a-TUBULIN, GAPDH or
VINCULIN were used as loading controls. When MDAMB231
cells were treated for 48 hours with conditioned medium (CM)
derived from miR-223 overexpressing HEK293 (HEK) cells,
decreased levels of STAT5A were observed compared to controls,
suggesting a transfer of miR-223 from CM to MDAMB231 cells
acting on STAT5A levels. VINCULIN was used as loading
control (Figure 5C).
Direct targeting was evaluated on STAT5A 39UTR in a
luciferase assay in miR-223 overexpressing and control (pre-miR-
223, pre-control) cells. When HeLa cells were co-transfected with
miR-223 and reporter vectors containing the full length wild type
(STAT5A) or mutated (STAT5AMUT) 39UTR or empty vectors,
a significant decrease in luciferase activity was specifically observed
when miR-223 was overexpressed with wild type but not mutant
STAT5A 39UTR reporter vector, indicating a direct targeting for
miR-223 on STAT5A 39UTR (Figure 5D).
Down-modulation of STAT5A Accounts for miR-223
Biological Effects
The potential role of STAT5A as a mediator of miR-223 effect
on transwell migration or paclitaxel (PTX) induced cell death was
evaluated in STAT5A-silenced MDAMB231 cells in which a 40%
reduction in protein expression was observed as assessed by
western blot analysis (Figure 6A). A 50% decrease was found in
cell migration, measured in a transwell assay (Figure 6B). In line
with these results, we observed increased transwell migration when
STAT5A was overexpressed in MDAMB231 cells (data not
shown). A 10–15% increase in PTX-induced cell death (Figure 6C)
was observed when cell survival was evaluated by Annexin V-
FITC and TMRM staining in FACS analysis following 48h of
PTX treatment. These data correlate the role of STAT5A with
miR-223 in cell movement and death.
Discussion
In this work we identified 6 microRNAs enriched in RNA
targets among genes differentially expressed in relapsing breast
cancer patients. Experimentally, we focused on miR-223 and
analyzed its role in cell death induced by chemotherapy
compounds and cell migration. We identified STAT5A as direct
target of miR-223 and correlated STAT5A with miR-223
functions.
MicroRNAs are well known to play a role in cancer progression
[56]. Despite the increasing interest to unravel their role in tumor
progression, few miRnomic screenings are available. Here, we
attempted microRNA alteration predictions starting from different
protein-coding gene profiling of breast cancers using various
prediction algorithms and further confirmed the results employing
another target reverse gene expression approach [47]. In this way
we identified miR-19ab, miR-200bc, miR-203, miR-21, miR-223
and miR-340 as putative players of breast cancer progression.
Relevantly, more datasets were used to better represent breast
cancer complexity while more algorithms were applied to reduce
false positive predictions as shown in [57]. The six predicted
microRNAs were already known to be involved in tumor
progression [28,58,59,60,61,62] and to be poorly expressed in
normal breast [63] while expressed in tumors, although diversely
in the various subtypes [13,14,63]. In particular, miR-19 was
reported to be upregulated in the Basal subtypes, miR-200c
downregulated in Normal-like tumors and miR-223 downmodu-
lated in luminal-B breast cancers [64]. Moreover miR-223 was
found differentially expressed in ER+ and ER- tumors [13,46,65].
Subtype-dependent microRNA expression could explain why it is
hard to observe differential microRNA expression in total, often
unbalanced datasets, by analyzing tumor prognosis (positive or
negative relapse). Since our microRNA predictions originated
from down-regulated protein-coding genes in tumors with bad
prognosis, one could expect an upregulation of the putative
microRNAs in Relapse positive versus Relapse negative tumors.
However, from our analyses and from similar investigations
[13,64] anti-correlations between microRNAs and targets do not
always occur, considering gene expression for tumor samples or
cell lines. This could be related to specific features of each
microRNA or to the biological systems considered. In addition,
circuits with feedback loops involving targets and microRNAs [66]
are present in cells, leading to unexpected correlation patterns
between the expression levels of microRNAs and their targets.
Clearly our approach is not free of limitations. For sure, we did
not predict all the microRNAs involved in breast cancer
progression due to the datasets and methodology we used and it
is not possible to speculate on their biological role without
functional data obtained from cell cultures. Regarding each
microRNA function, we are now investigating it in cells and here
we present some data relative to miR-223. Considering that our
expression analyses revealed that miR-223 is not present in tumor
cell lines in culture, while it is expressed in stroma cells, we
hypothesized a possible tumor-stroma interaction within the tumor
Table 2. Diseases and functions related to miR-223 predicted
targets.
Disease and disorders
Name p-value # Molecules
Cancer 1.38E-07–6.33E-03 582
Neurological Disorder 6.80E-06–7.00E-03 306
Developmental Disorder 1.02E-05–7.00E-03 182
Gastrointestinal Disease 2.09E-05–6.33E-03 107
Organismal Injury and Abnormalities 2.33E-05–7.00E-03 145
Molecular and cellular functions
Name p-value # Molecules
Cell Death and Survival 8.13E-09–6.56E-03 497
Gene Expression 2.12E-08–6.83E-03 357
Cellular Assembly and Organization 3.03E-08–7.00E-03 273
Cellular Function and Maintenance 3.03E-08–6.38E-03 384
Molecular Transport 2.25E-07–6.46E-03 332
N= 1995 targets for miR-223 predicted by at least two algorithms among
TargetScan, Miranda, miRBase (MicroCosm Targets) and DIANA-MicroT were
used to perform an Ingenuity Pathway Analysis (IPA). The top 5 enriched
Diseases and Disorders or Molecular and Cellular Functions are shown, scored by
p-values. The number of predicted miR-223 targets assigned to each group is
reported in the last column.
doi:10.1371/journal.pone.0084859.t002
miR-223 and Breast Cancer Progression
PLOS ONE | www.plosone.org 9 January 2014 | Volume 9 | Issue 1 | e84859
miR-223 and Breast Cancer Progression
PLOS ONE | www.plosone.org 10 January 2014 | Volume 9 | Issue 1 | e84859
Figure 5. Ingenuity Pathway Analysis of miR-223 predicted targets and STAT5A direct targeting. (A) The genes predicted to be miR-223
targets by at least two algorithms among TargetScan, Miranda, miRBase (MicroCosm Targets) and DIANA-MicroT were used to perform an Ingenuity
Pathway Analysis (IPA). The top 10 enriched signalling pathways are shown; the dark grey bars represent the -log(p-values) for the members of each
pathway (referring to the left Y-axes), the threshold line was set at –log (0.05) for statistical significance. The ratio between miR-223 predicted targets
(numbers in each bar) and the total number of genes in each pathway (not shown) is indicated by light–grey squares in each bar (relative to the right
Y-axes). (B–C) Analysis of STAT5A, NRAS or ITGA3 protein levels by western blot in MDAMB231 or SUM149PT cells stably transduced with pLemiR
empty (empty) or miR-223 overexpression (miR-223) vectors or transiently transfected with miR-223 precursors or their negative controls (pre-miR-
223 or pre-control) or grown for 48 hours in conditioned medium (CM) collected from HEK293 (HEK) cells stably transduced with pLemiR empty
(empty) or miR-223 overexpression (miR-223) vectors. Protein modulations were calculated relative to controls, normalized on a-TUBULIN, GAPDH or
VINCULIN as loading controls and expressed as repression percentages. (D) Luciferase assays in HeLa cells cotransfected with empty (empty vector)
or wild-type (STAT5A) or mutant (STAT5Amut) pMIR-Luciferase reporter vectors, together with miR-223 precursors or negative controls (pre-miR-223
or pre-control). Results are shown as Firefly Luciferase activity normalized on Renilla Luciferase activity. Three to six biological independent
experiments were performed, each in triplicate. Triplicate means of each biological experiment are shown as box-plot. *P,0.05; **P,0.01;
***P,0.001. Bottom panel: human miR-223 sequence paired with a portion of the human STAT5A 39UTR including the wild type or mutant binding
site for miR-223.
doi:10.1371/journal.pone.0084859.g005
Figure 6. STAT5A downmodulation phenocopies miR-223 functions. MDAMB231 were transiently transfected with STAT5A siRNAs (si-
STAT5A) or negative controls (si-control) and protein levels (A) or transwell migration (B) or cell death induction upon paclitaxel (PTX) treatment (C)
were evaluated. (A) Protein modulations in STAT5A silenced cells were evaluated in western blot analysis and calculated relative to controls,
normalized on the GAPDH loading control and expressed as repression percentages. (B) Migration results are shown as mean6SEM (standard error
mean) of the area covered by migrated cells normalized to controls. (C) The percentage (%) of dead cells displayed in histograms as mean6SEM was
evaluated by TMRM and AnnexinV-FITC stainings in a FACS analysis. In bidimensional plots a representative image of HighTMRM-LowAnnexinV gate
(healthy cells) and LowTMRM-HighAnnexinV gate (dying cells) for each condition is shown. 3 independent biological experiments were performed in
triplicate (B) or duplicate (C) and pools or three biological experiments are shown and used for statistics. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0084859.g006
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mass. This is supported from data in the literature showing that
miR-223 can be transferred to breast tumor cells from bone
marrow stroma [67] or microvesicles derived from IL-4 activated
macrophages [17]. In addition, the analysis of RNA from punches
of tumor or stroma components of breast samples revealed that
miR-223 is equally present in the two tumor portions. We further
confirmed that conditioned medium (CM) from miR-223 overex-
pressing fibroblasts or HEK293 cells led to increased miR-223
expression in MDAMB231 cells suggesting a transfer of miR-223
from cell to cell. We exclude an induction of endogenous miR-223
in MDAMB231 cells by secreted factors present in the CM (i.e.
growth factors, cytokines), since CM from miR-223-empty cells
does not affect miR-223 expression in MDAMB231 cells.
Biological analyses on miR-223 overexpressing cells in culture,
following CM treatment or overexpression (pre-miR or expression
vectors), proved that miR-223 participates to relevant cell
functions. No effect was found on cell adhesion and proliferation
however a relevant inhibitory role was observed for miR-223 on
migration and invasion as well as on cell survival in anoikis
conditions or in presence of chemotherapeutic drugs suggesting
various interventions during tumor progression. Other micro-
RNAs have been shown to modulate malignancy. For instance,
miR-31 and miR-148b control several steps of metastatization
from anoikis to invasion and colonization [31,46]. The function of
miR-223 in tumors remains however still unclear and it depends
on the kind of analyzed tumor. miR-223 has an anti-proliferative
function in cervical and colon-rectal cancer through the targeting
of IGFR and FOXO1 [68,69] and it exerts an anti-metastatic role
in oesophageal carcinoma [70]. Instead, it increases proliferation
and invasion in gastric cancer [71]. In breast cancer, our findings
suggest a suppressive role for miR-223 in tumor progression,
similar to what proposed by [67] and more recently by Gong and
colleagues [72]. Relevantly, miR-223, like other microRNAs such
as miR-31 [73], miR-148b [46] and miR-200bc [74], is involved
in drug sensitivity, suggesting a potential function as adjuvant
therapy, as recently reported also by [75,76]. It is important to
note that overlapping functions of miR-223 and miR-148b could
be due to common target genes, in fact miR-148b shares four
nucleotides of the seed region with miR-223.
By using the Ingenuity Pathway Analysis (IPA) for the predicted
miR-223 targets, the involvement of miR-223 in cancer and
mainly in cell death emerged. Specific enrichment was found for
the already validated miR-223 targets, IGFR1 and E2F pro-
survival genes and for NRAS, ITGA3 and STAT-family members.
Due to the established role of NRAS, ITGA3 and STAT5 in
cancer progression and cell death/survival, we focused on them.
They were all expressed in breast cancer datasets used for the
analysis but only STAT5A was consistently differentially expressed
in the datasets used for prediction analysis. miR-223 over-
expression was able to downmodulate NRAS, ITGA3 and STAT5
expression at the protein level. In line with miR-223 function are
the evidences that integrins, in particular ITGA3 and ITGB1, are
key mediators of the outside-in and inside-out signalling in cancer
and their depletion leads to decreased migratory abilities and
inhibition of metastasis formation [77]. Importantly, they are
exploited as possible anti-breast cancer targets [77]. Instead,
NRAS is a well-known oncogene, often constitutively active in
breast cancer, along with PI3K members and regulators, which
are also miR-223 predicted targets. Cells with altered NRAS fail to
respond to normal chemotherapeutic treatments and its down-
modulation is pursued with different approaches to increase
chemotherapy efficacy [78]. STAT5s are transcription factors
whose activation needs to be tightly controlled for mammary gland
development, lactation and involution [79] and some microRNAs
(i.e. miR-222) have been recently found to control STAT5
expression [80]. They are downstream players and crosstalk points
of many extracellular signals activated in response to interleukins
and growth factors [81]. In non-invasive breast cancer cell lines,
STAT5 activation was reported to increase colony formation,
invasion and migration via the AKT signalling [82]; while in
T47D its activation increases chemotherapy resistance [83].
STAT5A silencing instead leads to better chemotherapy response
in leukemia [84,85]. All these findings support our data, regarding
the involvement of miR-223 and its target STAT5A in both anti-
migratory and pro-chemotherapeutic effects and guide us to
configure miR-223 as a player of the microenvironment in breast
cancer. However, even if we proved that STAT5A is a direct
target for miR-223 with the luciferase assay, and observed that
decreased (RNAi) or increased (cDNA, data not shown) levels of
STAT5A lead to modulation of cell migration or chemotherapy
induced cell death, further rescuing experiments are necessary to
confirm that STAT5A is one of the main players of miR-223. So
far we only evidenced a functional correlation between miR223
and STAT5A. Other putative miR-223 targets are currently under
investigation.
In conclusion, we identified 6 microRNAs with a role in breast
cancer progression and unravelled some functions of miR-223, a
small RNA present in tumor and stroma cells, in breast cancer
samples. In the future, we will investigate the transfer mechanism
of miR-223 from stroma to tumor cells.
Supporting Information
Figure S1 miR-223 expression in stroma or tumor cell
areas of paraffin-embedded tumor samples. (A) Top-left:
a representative Hematoxilin&Eosin stained section of a paraffin-
embedded breast cancer sample. Punches were performed in the
embedded tumor in areas corresponding to stroma or tumor cells
as indicated by the circles. Magnification of tumor or stoma
punches are shown in the top-right or bottom. Levels of
magnifications are indicated. (B) Relative miR-21 and miR-223
levels of MDAMB231 cells line (reference) or of an infiltrated
lymph node (LN, control) or of stroma or tumor cell areas of
punches made in blocks of paraffin-embedded infiltrating ductal
carcinomas, as measured by qRT-PCR. Two punches for each
area of the sample were performed and pooled together for qRT-
PCR analyses. Four different blocks were used for stroma or tumor
area evaluation. Results are presented as fold changes (mean6SD)
relative to miR-223 level in MDAMB231 cells. The delta CT
mean of three technical replicates of one (LN) or four (Stroma or
Tumors) biological samples were used for statistics. Delta CTs
were obtained after normalization on U6sno RNA level.
SD= standard deviation; CT= threshold cycle number.
(TIF)
Figure S2 miR-223 expression levels in various cell
lines. (A–F) Relative miR-223 levels in Mouse Embryo
Fibroblasts (MEFs) (A) or HEK293 (B) or MDAMB231 (C–E)
or SUM149PT (F) cells wild type or previously transduced with
pLemiR empty (empty) or miR-223 overexpressing (miR-223)
vectors (A–C) or transfected with miR-223 precursors or their
negative controls (pre-miR-223 or pre-control) (D, F) or treated
with miR-223 overexpressing or control HEK293 (HEK)
conditioned medium (CM) (E). Results are presented as fold
changes (mean6SD) relative to controls of three technical
replicates of one representative biological sample. At least three
biological samples were analyzed. Delta CTs were obtained after
normalization on U6sno RNA level. SD= standard deviation.
*P,0.05; **P,0.01; ***P,0.001.
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(TIF)
Figure S3 Representative images of migration and
invasion experiments for miR-223. Representative images
of transwell migration (top) or matrigel invasion (bottom) assays
corresponding to Fig. 3. MDAMB231 cells were transfected with
miR-223 or unrelated miR precursors or their negative controls
(pre-miR-223 or unrelated pre-miR or pre-control) or stably
transduced with pLemiR empty (empty) or miR-223 overexpres-
sion (miR-223) vectors or pre-treated for 48 h with conditioned
medium (CM) collected from stably transduced HEK293 (HEK)
cells (CM HEK empty or CM HEK miR-223).
(TIF)
Figure S4 Representative images of FACS analysis plots
for cell death evaluation. Referring to Fig. 4, representative
images of bidimensional plots of HighTMRM-LowAnnexinV gate
(healthy cells) and LowTMRM-HighAnnexinV gate (dying cells) of
MDAMB231 cells for anoikis experiments (A) or Doxorubicin
(DOXO) (B) or Paclitaxel (PTX) treatments, in presence or
absence of ZVAD (C–E). Cells were transiently transfected with
miR-223 or with unrelated miR precursors or their negative
controls (pre-miR-223 or unrelated pre-miR or pre-control).
Alternatively MDAMB231 cells were grown for 48 h in condition
medium (CM) collected from HEK293 (HEK) cells stably
transduced with pLemiR empty (empty) or miR-223 overexpres-
sion (miR-223) vectors and further transferred to regular medium
without (Basal) or with PTX for 48 hours and cell death was
analyzed (D). For Annexin-APC stained cells (E) a further gate of
LowTMRM-LowAnnexinV cells was revealed. Therefore, an
additional plot showing the percentage (%) of viable cells after
Annexin-FITC Propidium Iodide (PI) staining is presented in (F).
LowPI-LowAnnexinV gate was reported in the histogram as % of
the total cell number. Two independent biological experiments
were performed in duplicate and a representative one is shown. In
(F) duplicates are used for statistics. *P,0.05; **P,0.01;
***P,0.001.
(TIF)
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